"Dose finding has been a challenge for the field of gene therapy, and while AAV remains a very safe delivery system, we should expect as with any biologic product that unexpected dose-limiting toxicities may be encountered," said Szilárd Kiss, MD, associate professor of ophthalmology and scientific advisory board member, Adverum. "It is important to learn from the data generated by this field to bring new treatments with durable efficacy and well-managed safety to patients."